Alnylam Pharmaceuticals (ALNY) Current Assets (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Current Assets data on file, last reported at $4.6 billion in Q2 2026.

• Quarterly Current Assets rose 26.8% year-over-year to $4.6 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $4.6 billion (up 26.8% YoY) and the FY2025 annual result came in at $4.1 billion, up 22.92% from the prior year.
• Current Assets advanced to $4.6 billion in Q2 2026, from $4.2 billion in the prior quarter.
• In the past five years, Current Assets ranged from a high of $4.6 billion in Q2 2026 to a low of $2.5 billion in Q2 2022.
• A 5-year average of $3.2 billion and a median of $3.1 billion in 2024 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2022 — Current Assets decreased 9.3% — and 2026, when it rose 29.1%.
• Tracing ALNY's Current Assets over 5 years: stood at $2.7 billion in 2022, then climbed by 10.79% to $3.0 billion in 2023, then rose by 10.48% to $3.3 billion in 2024, then advanced by 22.92% to $4.1 billion in 2025, then grew by 14.06% to $4.6 billion in 2026.
• The last three Current Assets figures came in at $4.6 billion (Q2 2026), $4.2 billion (Q1 2026), and $4.1 billion (Q4 2025), per Business Quant data.